Synonyms: compound 195 [WO2021113557A1] | NX5948
Compound class:
Synthetic organic
Comment: NX-5948 (Nurix Therapeutics) is an oral BTK protein degrader. It was designed as an alternative to BTK inhibitors for potential to treat B cell malignancies, including those that carry BTK mutations which confer resistance to existing BTK inhibitors [1-2]. In contrast to NX-2127 which degrades both BTK and IKZF3, NX-5948 selectively degrades BTK. We believe NX-5948 is compound 195 in patent WO2021113557A1 [3].
|
|
Immunopharmacology Comments |
Degradation of the BTK protein is an approach that is being investigated as an alternative to small molecule BTK inhibitors, for the treatment for B cell lymphomas. It is proposed that protein degradation will be effective in malignancies with BTK mutations that mediate resistance to existing BTK inhibitors. |